<SEC-DOCUMENT>0002044285-25-000012.txt : 20251114
<SEC-HEADER>0002044285-25-000012.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114124818
ACCESSION NUMBER:		0002044285-25-000012
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-50612
		FILM NUMBER:		251483723

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dauntless Investment Group, LLC
		CENTRAL INDEX KEY:			0002044285
		ORGANIZATION NAME:           	
		EIN:				994741394
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		3283 FOXFIRE DR.
		CITY:			MILFORD
		STATE:			MI
		ZIP:			48380
		BUSINESS PHONE:		734-770-0040

	MAIL ADDRESS:	
		STREET 1:		3283 FOXFIRE DR.
		CITY:			MILFORD
		STATE:			MI
		ZIP:			48380
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001137439-25-000639</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002044285</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>American Depository Shares</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001075880</issuerCik>
        <issuerName>KAZIA THERAPEUTICS LTD</issuerName>
        <issuerCusip>48669G105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>Three International Towers, Level 24</com:street1>
          <com:street2>300 Barangaroo Avenue</com:street2>
          <com:city>SYDNEY NSW</com:city>
          <com:stateOrCountry>C3</com:stateOrCountry>
          <com:zipCode>2000</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Dauntless Investment Group, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>176822.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>176822.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Single Family Office/Passive Investor</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>KAZIA THERAPEUTICS LTD</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Three International Towers, Level 24, 300 Barangaroo Avenue, SYDNEY NSW, AUSTRALIA, 2000.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Dauntless Investment Group, LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>3283 Foxfire Dr., Milford, MI 48380</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>176,822

The reporting person?s ownership consists of (i) 144,595 American Depository Shares and (ii) 32,227 Pre-funded Warrants; however, due to the exercise limitations of the Pre-funded Warrants, the reporting person?s beneficial ownership has been limited to 176,822 shares in the aggregate.</amountBeneficiallyOwned>
        <classPercent>9.99%

Each of the Pre-funded Warrants includes a provision limiting the holder?s ability to exercise the Pre-funded Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of Kazia Therapeutics Limited.

</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>176,822</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Dauntless Investment Group, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/Matthew Okkerse</signature>
        <title>CFO</title>
        <date>11/13/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
